Skip to main content
Hansa Biopharma logo

Hansa Biopharma — Investor Relations & Filings

Ticker · HNSA ISIN · SE0002148817 LEI · 549300LLEO25ZJJ3NT91 ST Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2018-03-20 Board/Management Inform…
Country SE Sweden
Listing ST HNSA

About Hansa Biopharma

https://www.hansabiopharma.com/

Hansa Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes treatments for rare immunologic diseases. The company's core focus is its proprietary antibody-cleaving enzyme technology platform, designed to target and inactivate immunoglobulin G (IgG) antibodies. This approach aims to inhibit harmful IgG-mediated immune responses. Its lead product, imilfidase, is used to enable kidney transplantation in highly sensitized patients who have a low probability of finding a compatible donor. The company is also advancing its enzyme technology to address unmet medical needs in other therapeutic areas, including acute autoimmune diseases, gene therapy, and oncology, where IgG antibodies can be a barrier to treatment or a driver of the disease.

Recent filings

Filing Released Lang Actions
Søren Tulstrup utsedd till ny VD och koncernchef för Hansa Medical
Board/Management Information Classification · 98% confidence The document is a press release dated March 20, 2018, announcing the appointment of Søren Tulstrup as the new CEO and Group President of Hansa Medical, effective immediately. It details the transition of the interim CEO and the background of the new CEO. This type of announcement, concerning changes in senior management or the board of directors, directly corresponds to the definition of Board/Management Information (MANG). The text does not relate to financial results (ER, IR), shareholder votes (DVA), or general regulatory filings (RNS), but specifically to executive personnel changes.
2018-03-20 Swedish
Søren Tulstrup appointed new President and CEO of Hansa Medical
Board/Management Information Classification · 99% confidence The document is explicitly titled as a "PRESS RELEASE" and announces the appointment of a new President and CEO, Søren Tulstrup. This action directly relates to changes in the company's senior management team. According to the definitions, 'Board/Management Information (Code: MANG)' covers the 'Announcement of changes in the company's board of directors or senior management.' The document is not a full financial report (10-K, IR), a transcript (CT), or a dividend notice (DIV). Therefore, MANG is the most appropriate classification.
2018-03-20 English
Hansa Medical beviljas särläkemedelsstatus för IdeS och behandling av Guillain-Barrés syndrom i USA
Regulatory Filings Classification · 95% confidence The document is a 'PRESSMEDDELANDE' (Press Release) dated February 16, 2018, announcing that Hansa Medical has been granted Orphan Drug Designation by the FDA for its drug candidate IdeS for the treatment of Guillain-Barré syndrome. This is a specific corporate announcement regarding regulatory progress and clinical development, not a full financial report (like 10-K or IR), a transcript (CT), or a general dividend/share change notice. It is a specific type of regulatory/corporate update. Since it is a press release detailing a specific regulatory event (FDA designation) and includes commentary from management, it fits best under the general 'Regulatory Filings' (RNS) category as a specific corporate event announcement, or potentially 'LTR' if it were about legal proceedings, but 'RNS' is the best fit for general, non-financial regulatory news releases that don't fit other specific categories like DIV, SHA, or CAP. Given the options, RNS (Regulatory Filings) serves as the appropriate catch-all for significant, non-financial regulatory news releases.
2018-02-16 Swedish
Hansa Medical receives FDA Orphan Drug Designation for IdeS and the treatment of Guillain-Barré syndrome
Regulatory Filings Classification · 95% confidence The document is explicitly labeled as a "PRESS RELEASE" and announces a specific regulatory event: Hansa Medical receiving Orphan Drug Designation (ODD) from the FDA for its drug IdeS concerning Guillain-Barré syndrome (GBS). It includes quotes, scientific background, and contact information typical of a corporate announcement. It is not a full financial report (10-K, IR), a transcript (CT), or a formal shareholder document (DEF 14A, PSI). Since it is a specific, non-financial regulatory/corporate event announcement that doesn't fit the other specific categories (like DIRS, DIV, CAP), the most appropriate general category for a significant, non-financial regulatory update that is not a standard financial filing is 'Regulatory Filings' (RNS), as it serves as a general regulatory announcement. However, given the nature of the announcement (FDA designation), it is a specific corporate update. If 'RNS' is used as a catch-all, it fits. If we look closely at the definitions, none perfectly capture an 'FDA Designation Announcement'. Since it is a formal announcement of a regulatory milestone, RNS is the best fit among the provided options, acting as the miscellaneous regulatory announcement category.
2018-02-16 English
Interim / Quarterly Report 2017
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Year-End Report 2017' and contains comprehensive financial statements, a CEO statement, business highlights, and a financial review for the full fiscal year. It provides substantive financial data and analysis, fitting the definition of an Interim/Quarterly Report (which covers periods shorter than a full fiscal year or, in this case, a year-end report serving as the primary financial disclosure). It is not a mere announcement (RPA) as it contains the full report content. FY 2017
2018-02-14 English
Interim / Quarterly Report 2017
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Bokslutskommuniké 2017' (Year-end Report 2017) for Hansa Medical. It contains comprehensive financial summaries, including income statements, balance sheets, and cash flow data for the fourth quarter and the full year 2017. It also includes a management discussion (Vd har ordet), business overview, and clinical trial updates. Since it covers a period shorter than a full fiscal year (Q4) and provides substantive financial data and analysis, it is classified as an Interim/Quarterly Report. FY 2017
2018-02-14 Swedish

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.